Vanguard Group Inc. Increases Holdings in Omeros Corporation $OMER

Key Points

• Vanguard Group Inc. increased its stake in Omeros Corporation by 3.0%, now holding approximately 3.24 million shares valued at $26.61 million.
• Omeros reported a quarterly earnings per share (EPS) of ($0.53), exceeding the consensus estimate of ($0.55), with revenue for the quarter at $28.60 million.
• The stock has a consensus rating of "Moderate Buy" among analysts, with an average price target of $18.00.

Vanguard Group Inc. raised its holdings in Omeros Corporation (NASDAQ:OMER - Free Report) by 3.0% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,237,256 shares of the biopharmaceutical company's stock after purchasing an additional 95,599 shares during the quarter. Vanguard Group Inc. owned 5.55% of Omeros worth $26,610,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently bought and sold shares of the company. Tower Research Capital LLC TRC grew its stake in Omeros by 79.0% in the 4th quarter. Tower Research Capital LLC TRC now owns 4,467 shares of the biopharmaceutical company's stock valued at $44,000 after purchasing an additional 1,972 shares during the period. GAMMA Investing LLC grew its stake in shares of Omeros by 14,486.3% during the 1st quarter. GAMMA Investing LLC now owns 7,439 shares of the biopharmaceutical company's stock worth $61,000 after acquiring an additional 7,388 shares during the period. Harbour Investments Inc. grew its stake in shares of Omeros by 51.9% during the 1st quarter. Harbour Investments Inc. now owns 9,218 shares of the biopharmaceutical company's stock worth $76,000 after acquiring an additional 3,149 shares during the period. Sowell Financial Services LLC bought a new position in shares of Omeros during the 1st quarter worth $88,000. Finally, Raymond James Financial Inc. bought a new position in shares of Omeros during the 4th quarter worth $124,000. Institutional investors own 48.79% of the company's stock.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on OMER shares. Wall Street Zen downgraded Omeros from a "hold" rating to a "sell" rating in a research note on Friday, June 27th. D. Boral Capital reiterated a "buy" rating and set a $36.00 price target on shares of Omeros in a research note on Wednesday. Needham & Company LLC reiterated a "hold" rating on shares of Omeros in a research note on Friday, August 15th. Finally, HC Wainwright reiterated a "buy" rating and set a $9.00 price target on shares of Omeros in a research note on Friday, June 27th. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $18.00.

Omeros Price Performance

Shares of NASDAQ:OMER traded down $0.11 on Wednesday, hitting $4.18. The company's stock had a trading volume of 767,814 shares, compared to its average volume of 995,136. The company has a 50-day simple moving average of $3.82 and a 200 day simple moving average of $5.38. Omeros Corporation has a 1 year low of $2.95 and a 1 year high of $13.60. The company has a market capitalization of $284.49 million, a PE ratio of -1.98 and a beta of 2.37.

Omeros (NASDAQ:OMER - Get Free Report) last released its quarterly earnings results on Thursday, August 14th. The biopharmaceutical company reported ($0.53) earnings per share for the quarter, beating the consensus estimate of ($0.55) by $0.02. The business had revenue of $28.60 million during the quarter, compared to analysts' expectations of $0.31 million. On average, equities research analysts expect that Omeros Corporation will post -3.09 earnings per share for the current fiscal year.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.